Given the link between the GluA1 and GluA2 subunits and tau pathology, our data provide novel insights into the role of AMPARS in mediating synaptic dysfunctions and offer avenues for the development of novel therapeutics for AD. Here, MAPT is linked to Alzheimer disease.